Morgan Stanley analyst Judah Frommer raised the firm's price target on Belite Bio to $201 from $191 and keeps an Overweight rating on the shares. The company's Q4 update included narrowing timing for expected tinlarebant NDA submission to the FDA to Q2 and management reiterated expectations for a broad label, the analyst tells investors.
